Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Anti-Obesity Drugs Market, by Drug Type
1.4.2 Europe Anti-Obesity Drugs Market, by Mechanism of Action
1.4.3 Europe Anti-Obesity Drugs Market, by Route Of Administration
1.4.4 Europe Anti-Obesity Drugs Market, by Distribution Channel
1.4.5 Europe Anti-Obesity Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Anti-Obesity Drugs Market by Drug Type
3.1 Europe Prescription Drugs Market by Country
3.2 Europe Over The Counter Drugs Market by Country
Chapter 4. Europe Anti-Obesity Drugs Market by Mechanism of Action
4.1 Europe Centrally Acting Market by Country
4.2 Europe Peripherally Acting Market by Country
Chapter 5. Europe Anti-Obesity Drugs Market by Route Of Administration
5.1 Europe Oral Route Market by Country
5.2 Europe Subcutaneous Route Market by Country
Chapter 6. Europe Anti-Obesity Drugs Market by Distribution Channel
6.1 Europe Hospital Pharmacies Market by Country
6.2 Europe Retail Pharmacies Market by Country
6.3 Europe Online Pharmacies Market by Country
Chapter 7. Europe Anti-Obesity Drugs Market by Country
7.1 Germany Anti-Obesity Drugs Market
7.1.1 Germany Anti-Obesity Drugs Market by Drug Type
7.1.2 Germany Anti-Obesity Drugs Market by Mechanism of Action
7.1.3 Germany Anti-Obesity Drugs Market by Route Of Administration
7.1.4 Germany Anti-Obesity Drugs Market by Distribution Channel
7.2 UK Anti-Obesity Drugs Market
7.2.1 UK Anti-Obesity Drugs Market by Drug Type
7.2.2 UK Anti-Obesity Drugs Market by Mechanism of Action
7.2.3 UK Anti-Obesity Drugs Market by Route Of Administration
7.2.4 UK Anti-Obesity Drugs Market by Distribution Channel
7.3 France Anti-Obesity Drugs Market
7.3.1 France Anti-Obesity Drugs Market by Drug Type
7.3.2 France Anti-Obesity Drugs Market by Mechanism of Action
7.3.3 France Anti-Obesity Drugs Market by Route Of Administration
7.3.4 France Anti-Obesity Drugs Market by Distribution Channel
7.4 Russia Anti-Obesity Drugs Market
7.4.1 Russia Anti-Obesity Drugs Market by Drug Type
7.4.2 Russia Anti-Obesity Drugs Market by Mechanism of Action
7.4.3 Russia Anti-Obesity Drugs Market by Route Of Administration
7.4.4 Russia Anti-Obesity Drugs Market by Distribution Channel
7.5 Spain Anti-Obesity Drugs Market
7.5.1 Spain Anti-Obesity Drugs Market by Drug Type
7.5.2 Spain Anti-Obesity Drugs Market by Mechanism of Action
7.5.3 Spain Anti-Obesity Drugs Market by Route Of Administration
7.5.4 Spain Anti-Obesity Drugs Market by Distribution Channel
7.6 Italy Anti-Obesity Drugs Market
7.6.1 Italy Anti-Obesity Drugs Market by Drug Type
7.6.2 Italy Anti-Obesity Drugs Market by Mechanism of Action
7.6.3 Italy Anti-Obesity Drugs Market by Route Of Administration
7.6.4 Italy Anti-Obesity Drugs Market by Distribution Channel
7.7 Rest of Europe Anti-Obesity Drugs Market
7.7.1 Rest of Europe Anti-Obesity Drugs Market by Drug Type
7.7.2 Rest of Europe Anti-Obesity Drugs Market by Mechanism of Action
7.7.3 Rest of Europe Anti-Obesity Drugs Market by Route Of Administration
7.7.4 Rest of Europe Anti-Obesity Drugs Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Pfizer, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional & Segmental Analysis
8.1.4 Research & Development Expense
8.2 Boehringer Ingelheim International Gmbh
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional & Segmental Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.3 GlaxoSmithKline PLC (GSK)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Acquisition and Mergers:
8.4 Novo Nordisk A/S
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental & Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Approvals and Trials:
8.5 Rhythm Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expenses
8.6 Gelesis Holdings Inc (PureTech Health)
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Research & Development Expenses
8.6.4 Recent strategies and developments:
8.6.4.1 Partnerships, Collaborations, and Agreements:
8.6.4.2 Approvals and Trials:
8.7 Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
8.7.1 Company Overview
8.7.2 Recent strategies and developments:
8.7.2.1 Acquisition and Mergers:
8.8 Vivus LLC
8.8.1 Company Overview
8.8.2 Recent strategies and developments:
8.8.2.1 Approvals and Trials:
8.9 CHEPLAPHARM Arzneimittel GmbH (Braun Beteiligungs GmbH)
8.9.1 Company Overview
8.10. KVK Tech, Inc.
8.10.1 Company Overview
Unique Offerings 